Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
| Brand name | VALSARTAN AND HYDROCHLOROTHIAZIDE |
| Generic name | VALSARTAN AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE, VALSARTAN |
| Distributed by / for | Aurobindo Pharma USA, Inc., Dayton, NJ 08810 |
| NDC | 65862-550-90 |
| Full product label | Valsartan and Hydrochlorothiazide tablets USP 320mg/12.5 mg, 90-count bottle, Rx Only, Manufactured for: Aurobindo Pharma USA, Inc., Dayton, NJ 08810. NDC 65862-550-90. |
| Recalling firm | Aurobindo Pharma USA Inc. |
| Distribution | Product was distributed to 25 distributors and Retail Chains who may have further distributed the product throughout the United States. |
| Quantity | 23,016 bottles |
| Recall initiated | 2018-12-31 |
| Report date | 2019-01-23 |
| Recall completed | — |
| Recall number | D-0365-2019 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | East Windsor NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗